Surgeon General Nominee Linked Cannabis to Gynecomastia in Past Remarks

President Donald Trump's nominee for U.S. Surgeon General has previously stated that marijuana use can cause gynecomastia—enlarged breast tissue in men—though she has also recognized potential therapeutic applications for medical cannabis.

Dr. Nicole Saphier, a radiologist and Fox News medical contributor, made the comments about cannabis and male breast development during past media appearances, according to reports. Trump announced her nomination Thursday.

The remarks highlight potential friction between the nominee and a cannabis industry that has grown to over $30 billion annually in the United States. Federal health officials wield significant influence over drug scheduling recommendations and public health messaging around cannabis.

The Medical Context

Research indicates that chronic, heavy cannabis use may influence hormone levels in some individuals. THC can affect testosterone production and estrogen metabolism, though the clinical significance remains debated among endocrinologists. Some studies have documented cases of gynecomastia in heavy cannabis users, but establishing direct causation has proven difficult given confounding variables.

The condition typically requires sustained, high-dose exposure and doesn't affect most cannabis consumers. Clinical evidence shows gynecomastia occurs in approximately 1-2% of the general male population regardless of cannabis use.

Dr. Saphier has also acknowledged what she termed "potential benefits" of medical cannabis, suggesting her position isn't categorically opposed to therapeutic applications. That nuance matters as the Department of Health and Human Services reviews marijuana's Schedule I classification.

Industry Implications

The Surgeon General serves as the nation's top spokesperson on public health matters. While the position lacks direct regulatory authority over cannabis, the bully pulpit influences public perception and policy debates.

"Federal health officials shape the conversation around cannabis safety," said one industry lobbyist who requested anonymity to speak candidly. "Their statements carry weight with lawmakers still on the fence about reform."

The cannabis industry has invested heavily in research demonstrating safety profiles comparable to or better than alcohol. Major operators like Curaleaf and Trulieve have funded studies examining therapeutic applications for conditions ranging from chronic pain to PTSD.

But concerns about hormonal effects, particularly in adolescents, remain legitimate areas of scientific inquiry. Responsible industry groups have acknowledged the need for age restrictions and dosing guidelines.

What's Next

Dr. Saphier must undergo Senate confirmation hearings before assuming the role. Senators from states with legal cannabis markets—including Democratic Majority Leader Chuck Schumer of New York—may press her on how she'd approach marijuana policy.

The timing coincides with ongoing federal rescheduling proceedings. The Drug Enforcement Administration is reviewing HHS recommendations to move cannabis from Schedule I to Schedule III, a change that would acknowledge medical value while maintaining federal controls.

Trump himself has expressed support for state-level cannabis legalization and backed Florida's recreational marijuana ballot measure in 2024. How that translates to his administration's public health messaging remains unclear.

The Senate Health, Education, Labor and Pensions Committee typically handles Surgeon General nominations. A confirmation vote could occur within 60-90 days if the process moves smoothly.

---

This article is based on original reporting by www.marijuanamoment.net.